Evidence map›Paper›PMID 39144475›Full record

ArticleGlomerular diseases

Effects of Dapagliflozin in Patients with Membranous Nephropathy.

Glenn M Chertow, Hiddo Lambers Heerspink, Patrick B Mark, Jamie P Dwyer, Michal Nowicki, David C Wheeler, Ricardo Correa-Rotter, Peter Rossing, Robert D Toto, Anna Maria Langkilde and 1 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Glomerular diseases. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed.

  1. Article
  2. Review
  3. Review
  4. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors.

Glenn M ChertowDepartments of Medicine, Epidemiology and Population Health, and Health Policy, Stanford University School of Medicine, Stanford, CA, USA.
Hiddo Lambers HeerspinkDepartment of Clinical Pharmacy and Pharmacology, University of Groningen, University Medical Center Groningen, Groningen, The Netherlands.
Patrick B MarkSchool of Cardiovascular and Metabolic Health, University of Glasgow, Glasgow, UK.
Jamie P DwyerDivision of Nephrology and Hypertension, University of Utah, Salt Lake City, UT, USA.
Michal NowickiDepartment of Nephrology, Hypertension and Kidney Transplantation, Central University Hospital, Medical University of Lodz, Lodz, Poland.
David C WheelerDepartment of Renal Medicine, University College London, London, UK.
Ricardo Correa-RotterThe National Medical Science and Nutrition Institute Salvador Zubiran, Mexico City, Mexico.
Peter RossingSteno Diabetes Center Copenhagen, Herlev, Denmark.
Robert D TotoDepartment of Internal Medicine, UT Southwestern Medical Center, Dallas, TX, USA.
Anna Maria LangkildeBioPharmaceuticals R&D, AstraZeneca, Gothenburg, Sweden.
Niels JongsDepartment of Clinical Pharmacy and Pharmacology, University of Groningen, University Medical Center Groningen, Groningen, The Netherlands.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Introduction: Despite the provision of renin-angiotensin-aldosterone-system inhibitors and immunosuppressive therapies, membranous nephropathy often progresses to end-stage kidney disease (ESKD). The objective of this prespecified analysis was to assess the safety and efficacy of dapagliflozin in patients with membranous nephropathy enrolled in the DAPA-CKD trial. Methods: Patients with an estimated glomerular filtration rate (eGFR) of 25-75 mL/min/1.73 m Results: Among DAPA-CKD participants with membranous nephropathy, 19 were randomized to dapagliflozin and 24 to placebo. The mean (SD) age was 59.9 ± 12.1 years, the mean eGFR was 45.7 ± 12.1 mL/min/1.73 m Conclusion: In membranous nephropathy, the effects of dapagliflozin on kidney disease progression and albuminuria were generally favorable; there was insufficient power to justify formal inference testing.

Indexed as

Chronic kidney diseaseDapagliflozinEstimated glomerular filtration rateMembranous nephropathySodium-glucose cotransporter 2 inhibitor

Identifiers

PMID39144475
PMCPMC11324228

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.